M&A

News

Lilly's M&A team strikes again with $2.3bn Ajax takeover

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.

News

Four hands, each with a puzzle piece, coming together in the centre

Sun sets out $11.75bn takeover play for Organon

After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.

News

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

Lilly's M&A team strikes again with $2.3bn Ajax takeover

Sun sets out $11.75bn takeover play for Organon

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Gilead strikes again, penning $5bn deal to buy Tubulis

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks